117 related articles for article (PubMed ID: 9090717)
1. Pharmacodynamic evaluation of mitomycin C analog BMS-181174 for potential use in intravesical bladder cancer therapy.
Yen WC; Au JL
Pharm Res; 1997 Feb; 14(2):241-5. PubMed ID: 9090717
[No Abstract] [Full Text] [Related]
2. Transitional cell carcinoma of the prostate following intravesical therapy for transitional cell carcinoma of the bladder.
Hardeman SW; Perry A; Soloway MS
J Urol; 1988 Aug; 140(2):289-92. PubMed ID: 3135420
[TBL] [Abstract][Full Text] [Related]
3. Severe bladder contracture in patient receiving intravesical mitomycin C for superficial bladder cancer.
Baker WC; Russo MA; deVere White RW
Urology; 1987 Oct; 30(4):357-8. PubMed ID: 3116739
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a BMS-181174-resistant human bladder cancer cell line.
Xia H; Bleicher RJ; Hu X; Srivastava SK; Gupta V; Zaren HA; Singh SV
Br J Cancer; 1997; 76(4):461-6. PubMed ID: 9275022
[TBL] [Abstract][Full Text] [Related]
5. [Study of the synergy of microwave hyperthermia/intravesical chemotherapy in the prevention of recurrences of superficial tumors of the bladder].
Mauroy B; Bonnal JL; Prevost B; Chive M; Lhotellier V; Sozanski JP; Vanseymortier L; Stefaniak X
Prog Urol; 1999 Feb; 9(1):69-80. PubMed ID: 10212955
[TBL] [Abstract][Full Text] [Related]
6. Superficial bladder cancer: intravesical chemotherapy and tumour progression to muscle invasion or metastases.
Smith G; Elton RA; Chisholm GD; Newsam JE; Hargreave TB
Br J Urol; 1986 Dec; 58(6):659-63. PubMed ID: 3099881
[TBL] [Abstract][Full Text] [Related]
7. Use of intravesical cisplatin and mitomycin-C for recurrent transitional cell carcinoma of bladder refractory to thiotepa.
Mobley WC; Loening SA; Narayana AS; Culp DA
Urology; 1986 Apr; 27(4):335-9. PubMed ID: 3083555
[TBL] [Abstract][Full Text] [Related]
8. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
[TBL] [Abstract][Full Text] [Related]
9. Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma.
Kalsi J; Harland SJ; Feneley MR
Expert Opin Drug Deliv; 2008 Jan; 5(1):137-45. PubMed ID: 18095933
[TBL] [Abstract][Full Text] [Related]
10. Bladder wall calcification after intravesical mitomycin C treatment of superficial bladder cancer.
Drago PC; Badalament RA; Lucas J; Drago JR
J Urol; 1989 Oct; 142(4):1071-2. PubMed ID: 2507794
[TBL] [Abstract][Full Text] [Related]
11. The effect of mitomycin C on superficial bladder cancer.
Soloway MS; Murphy WM; DeFuria MD; Crooke S; Finebaum P
J Urol; 1981 May; 125(5):646-8. PubMed ID: 6785454
[TBL] [Abstract][Full Text] [Related]
12. Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study.
Heney NM; Koontz WW; Barton B; Soloway M; Trump DL; Hazra T; Weinstein RS
J Urol; 1988 Dec; 140(6):1390-3. PubMed ID: 3143016
[TBL] [Abstract][Full Text] [Related]
13. [Chemosensitivity in established human bladder carcinoma and HELA cell lines in vitro].
Uchibayashi T
Nihon Hinyokika Gakkai Zasshi; 1983 Sep; 74(9):1606-20. PubMed ID: 6202921
[No Abstract] [Full Text] [Related]
14. Cultured human bladder tumors for pharmacodynamic studies.
Schmittgen TD; Au JL; Wientjes MG; Badalament RA; Drago JR
J Urol; 1991 Jan; 145(1):203-7. PubMed ID: 1898521
[TBL] [Abstract][Full Text] [Related]
15. Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-C. Comparison of exposure times.
Giesbers AA; Van Helsdingen PJ; Kramer AE
Br J Urol; 1989 Feb; 63(2):176-9. PubMed ID: 2495144
[TBL] [Abstract][Full Text] [Related]
16. [Pulmonary fibrosis following instillation of mitomycin C in the urinary bladder].
Neubauer H; Blech M; Wilhelms E; Crieé CP; Neuhaus KL; Truss F
Urologe A; 1987 Jan; 26(1):41-3. PubMed ID: 3107190
[TBL] [Abstract][Full Text] [Related]
17. Cytomorphological lesions induced by chemotherapeutic agents in transitional cell carcinoma in vitro.
Weaver DJ; Barrett BA; Ross G; Adelstein EH
In Vitro Cell Dev Biol; 1986 Nov; 22(11):653-60. PubMed ID: 3096952
[TBL] [Abstract][Full Text] [Related]
18. Lack of a role of glutathione in cellular nonenzymatic activation of BMS-181174, a novel analogue of mitomycin C.
Xia H; Pinto T; Hu X; Benson PJ; Zaren HA; Gupta V; Singh S
Cancer Res; 1996 Aug; 56(15):3495-8. PubMed ID: 8758917
[TBL] [Abstract][Full Text] [Related]
19. [Chemosensitivity test on superficial urinary bladder cancer using the dye exclusion assay--model of intravesical chemotherapy].
Koseki K; Irisawa C; Shiraiwa Y
Nihon Hinyokika Gakkai Zasshi; 1991 Feb; 82(2):268-73. PubMed ID: 1904118
[TBL] [Abstract][Full Text] [Related]
20. Treatment schedule of intravesical chemotherapy with mitomycin C in superficial bladder cancer: short-term courses or maintenance therapy.
van der Meijden AP; DeBruyne FM
Urology; 1988 Mar; 31(3 Suppl):26-9. PubMed ID: 3126592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
